Why is PLX up?
Up 123% over five years while the S&P 500 rose 68%.
- Free cash flow went from -$26.8M in fiscal 2020 to -$13.6M in fiscal 2025.
The company's words and the timeline, for Pro members.
Protalix BioTherapeutics (PLX) stock
$2.54
Quality Score
11
In its industry
#45of 281
Checks firing
3of 14
From 52-week high
-20.4%
PLX's Quality Score rose 2 points on Fri, Nov 6, to 11. Its price settled into a narrow range (2 chart checks started).
Follow PLX's trial news. Pro members can get an alert when Protalix BioTherapeutics files news, and see its trials, share raises, and its CEO's filings.
Get an alert when PLX files news on its trialSee it live, free for 24 hours. No account. No card. Then keep going with a free account.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Next2H 2027“…Phase 2 study continues to advance as planned, with top-line results anticipated in the second half of 2027”
Key facts on PLX
| The company | Sales up 30% on the year |
| Latest filing | 10-Q, Aug 12 |
1 more reason behind PLX's 11, free with an account →4 more reasons behind PLX's 11, for Pro members.
PLX in the news
ReportReports tomorrow, before the open. Every 3 months, a company tells everyone how much it sold and earned. It rose after 2 and fell after 2 of its last 4 reports, -5.4% on average. Past reports ›
What's next
Tue Nov 10: Stifel Healthcare Conference 2026Investor conference · date confirmed.
PLX catalysts
Coming up
After its last 4 reports it closed -5.4% on average, higher 2 of 4 times.
What's next for PLX
Next step the company has named
2H 2027“PRX-115 Phase 2 study continues to advance as planned, with top-line results anticipated in the second half of 2027”
Dilution on the horizon
- Shelf registration (S-3, filed Apr 28, 2025)
- At-the-market share sales program (424B5, filed Aug 22, 2025)
Insiders
CEO Dror Bashan bought 56,000 shares on Dec 19, 2025.
FDA dates in the next 60 days
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
Why PLX scores 11
Above Averagefor quality, not price, 3 of 14 chart checks firingWhat the Quality Score means
- +3Chart checks 3 of 14 firing right now, one point each
- +3Growth sales up 30% on the year, gross margin up 11.7 points
- Long-term trend adds
- Run-up adds
- Size subtracts
- Profit adds
- Persistence adds
What every line is worth, and the reason behind it, on PLX and every other stock.Get in free →
How PLX ranks in Biotech
PLX is #45 of 281 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 45 |
When does PLX report earnings, and what happens after?
Reports Tue Nov 10, before the open (tomorrow). Confirmed.
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
What PLX reported on Aug 12, 2026
The quarter
The figures are not read from the release yet.
“Revenues from selling goods increased to $19.8 million in the second quarter of 2026, up $4.4 million from the second quarter of 2025, driven primarily by sales of Elfabrio ®”
Where the sales came from
PLX's results filing gives no sales by line in a table we read.
The outlook
| Measure | Figure |
|---|---|
| Total revenue | $78M to $83M |
In the company's words
“Other than potential regulatory milestone payments, the Company expects to generate minimal revenues from license and R&D services going forward, having completed the clinical development of Elfabrio®.”
From its results filing (SEC filing · Aug 12)
The numbers
- $202M
- today
- $80.6M
- up 30.1% on the year
- $7.7M
- last 12 months
Sales fell 3.5% a year over 5 years, fiscal 2020 to 2025.
Close after the report, last 3
-20.8%+1.1%+7.8%
Mar 18May 13Aug 12
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Aug 12, 2026 | +2.5% | +7.8% | -3.7% |
| May 13, 2026 | +3.1% | +1.1% | -0.5% |
| Mar 18, 2026 | -18.3% | -20.8% | -25.8% |
PLX sales and profit by year
Sales grew in four of the last seven years, to $52.7M in 2025. It lost money in 2025 after a profit in 2024.
PLX has 3 of 14 chart checks firing
The other 10 checks on PLX, and all 14 on every stock.Get in free →
PLX RSI today: 45.2, below its 50-day, above its 200-day
RSI 45.2, MACD below signal, below its 50-day, above its 200-day. Not scored.
The deep dive on PLX
- What it does and how it makes moneyAnnual report, filed Mar 18, 2026
- Where it stands
- What changed in its filingsSEC filing · Mar 18, 2026, against the one of Mar 17, 2025
- Who holds and trades it
PLX's officers and directors
Officers and directors with a Form 4 in the last 12 months.
About Protalix BioTherapeutics
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.
What Protalix BioTherapeutics says it competes with
“The biotechnology and pharmaceutical industries are characterized by rapidly evolving technology and significant competition.”
Here is what Pro members see.
- Prices refresh every 2.5 seconds during market hours.
- Optional alerts by push, email, or the bell.
- Add it to your Home Screen and it opens like an app.
Pro members see every line of every stock's score.
- What would move PLX's score: 4 things
- 4 more filings explained, a plain line each
- Real-time prices, no delay
Straight AnswersStraight Answers
What does PLX's Quality Score say?
PLX scores 11 today, which Breakaway calls Above Average. It is #45 of 281 in Biotech by Quality Score, with 3 of 14 chart checks firing. Up 123% over five years while the S&P 500 rose 68%. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
What is PLX's Quality Score?
PLX scores 11 today, which Breakaway calls Above Average (11 to 14). That is #45 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind PLX's 11.
When does PLX report earnings?
Reports Tue Nov 10, before the open, a date the company confirmed. PLX closed higher after 2 of its last 4 reports. Past behavior, not a forecast.
Are the prices delayed?
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.